Last reviewed · How we verify
CHEMOTHERAPY then HORMONOTHERAPY — Competitive Intelligence Brief
phase 3
Combination chemotherapy and endocrine therapy regimen
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
CHEMOTHERAPY then HORMONOTHERAPY (CHEMOTHERAPY then HORMONOTHERAPY) — UNICANCER. A sequential treatment regimen that first uses chemotherapy to reduce tumor burden, followed by hormone therapy to suppress hormone-dependent cancer cell growth.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CHEMOTHERAPY then HORMONOTHERAPY TARGET | CHEMOTHERAPY then HORMONOTHERAPY | UNICANCER | phase 3 | Combination chemotherapy and endocrine therapy regimen |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Combination chemotherapy and endocrine therapy regimen class)
- UNICANCER · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CHEMOTHERAPY then HORMONOTHERAPY CI watch — RSS
- CHEMOTHERAPY then HORMONOTHERAPY CI watch — Atom
- CHEMOTHERAPY then HORMONOTHERAPY CI watch — JSON
- CHEMOTHERAPY then HORMONOTHERAPY alone — RSS
- Whole Combination chemotherapy and endocrine therapy regimen class — RSS
Cite this brief
Drug Landscape (2026). CHEMOTHERAPY then HORMONOTHERAPY — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotherapy-then-hormonotherapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab